RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112

Benzinga · 1d ago
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.